Disc Medicine (IRON) vs Tango Therapeutics (TNGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Tango Therapeutics (TNGX) has outperformed Disc Medicine (IRON) over the past year, gaining 116.7% versus a loss of 18.9%. Over five years, TNGX leads with a +110.0% price change compared with -14.2% for IRON. Tango Therapeutics is the larger company by market cap ($3.68 billion vs $3.42 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRON | TNGX |
|---|---|---|
| Share price | $75.14 | $21.73 |
| Market cap | $3.42B | $3.68B |
| 1-day change | -1.27% | -4.32% |
| YTD return | -5.38% | +145.26% |
| 1-year return | -18.86% | +116.65% |
| 5-year return | -14.22% | +109.95% |
| EPS (TTM) | $-6.34 | $-1.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $62.38M |
| Revenue growth (YoY) | — | +48.29% |
| Net income (latest FY) | $-212.18M | $-101.59M |
| Operating margin | — | -178.39% |
| Net margin | — | -162.85% |
| 52-week high | $99.50 | $34.39 |
| 52-week low | $40.00 | $8.30 |
| Distance from 52-week high | -24.48% | -36.81% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +69.94% | +116.29% |
| Average volume | 951.56K | 3.41M |
| Shares outstanding | 45.54M | 169.46M |
| Employees | 173 | 137 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TNGX has outperformed IRON by 135.5 percentage points over the past year.
About Disc Medicine
IRON stock →Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 173 employees
About Tango Therapeutics
TNGX stock →Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 137 employees
IRON vs TNGX FAQ
Which is bigger, Disc Medicine or Tango Therapeutics?
Tango Therapeutics (TNGX) is larger, with a market capitalization of $3.68B compared with $3.42B for Disc Medicine (IRON).
Which stock has performed better over the past year, IRON or TNGX?
TNGX returned +116.65% over the past 12 months, compared with -18.86% for IRON (price return, excluding dividends). Past performance does not predict future results.
Are Disc Medicine and Tango Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.